The St. Louis-born biopharmaceutical company has a new life and new focus, four months after its board sought to dissolve the ...

Shares of Puma Biotechnology, Inc. PBYI have rallied 24% in the past three months against the industry’s decline of 9.7%. The ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Anbio Biotechnology seeks IPO funding to expand in the IVD market. Discover why NNNN stock’s potential is tempered by ...

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

From proton therapy firsts to tumour-killing quantum dots, Tami Freeman shares her pick of this year’s healthcare innovations ...

Achieving biotech sovereignty will reduce dependency on foreign nations for critical products and technologies, ensuring ...

Anbio Biotechnology filed for a 1.6 million-share initial public offering with the Securities and Exchange Commission. The company said Tuesday it expects the IPO to price between $5 and $6 per share, ...

NEW YORK – Anbio Biotechnology filed this week a preliminary prospectus for an initial public offering on the Nasdaq exchange of 1.6 million shares at an anticipated offering price in the range of $5 ...

ANS-014004 is under development for the treatment of solid tumor and non small cell lung cancer (NSCLC). The therapeutic candidate is administered through oral route as tablet formulation. It acts by ...

Plandaí Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. It is developing Phytofare Catechin Complex ...

Mohali, is inviting applications for its prestigious PhD program in Biotechnology, commencing in January 2025, with research ...